BAFF - ling autoantibodies

5006 The Journal of Clinical Investigation http://www.jci.org Volume 123 Number 12 December 2013 1998;91(12):4397–4418. 5. Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and Factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N Engl J Med. 1980;302(19):1047–1051. 6. Ware J, et al. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor. Proc Natl Acad Sci U S A. 1991;88(7):2946–2950. 7. Celikel R, Ruggeri ZM, Varughese KI. von Willebrand factor conformation and adhesive function is modulated by an internalized water molecule. Nat Struct Biol. 2000;7(10):881–884. 8. Casari C, et al. von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αIIbβ3. J Clin Invest. 2013;123(12):5071–5081. 9. Murata M, Ware J, Ruggeri ZM. Site-directed mutagenesis of a soluble recombinant fragment of platelet glycoprotein Ibα demonstrating negatively charged residues involved in von Willebrand factor binding. J Biol Chem. 1991;266(23):15474–15480. 10. Othman M, Lopez JA, Ware J. Platelet-type von Willebrand disease update: the disease, the molecule and the animal model. Expert Rev Hematol. 2011;4(5):475–477. 11. Guerrero JA, et al. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelettype von Willebrand disease mutation. Blood. 2009;114(27):5541–5546. 12. Huizinga EG, et al. Structures of glycoprotein Ibα and its complex with von Willebrand factor A1 domain. Science. 2002;297(5584):1176–1179. important data to explain molecular consequences for a gain-of-function mutation in vWF many years after the recognition of type 2B as a distinct subtype of vWD.